MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Dobutamine 12.5 mg/mL Intravenous Injection (Solution, 20 mL)	FIN	F 008 740

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Dobutamine Hydrochloride, USP*	0.280	g				
Sodium Metabisulfite 1% Stock Solution †	0.4	mL				
Sodium Chloride, USP	0.127	g				
Sterile Water for Injection, USP	18.0	mL				
Sterile Water for Injection, USP	q.s. to 20.0	mL				
Hydrochloric Acid 10% Solution	As required					
Sodium Hydroxide 10% Solution	As required					
† **Sodium Metabisulfite 1% Stock Solution**						
Sodium Metabisulfite, NF	0.100	g				
Sterile Water for Injection, USP	9.0	mL				
Sterile Water for Injection, USP	q.s. to 10.0	mL				

*Dobutamine Hydrochloride 0.280 g is equivalent to Dobutamine 0.250 g.

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light Sensitive *(protect from light whenever possible):* *Dobutamine Hydrochloride, Sodium Metabisulfite*

Moisture Sensitive *(protect from humidity whenever possible):* *Sodium Metabisulfite*

Air Sensitive *(protect from air whenever possible):* *Sodium Metabisulfite*

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Dobutamine 12.5 mg/mL Intravenous Injection (Solution, 20 mL)	FIN	F 008 740

SPECIAL PREPARATORY CONSIDERATIONS (CONTINUED)

Suggested Preparatory Guidelines

☐ Non-Sterile Preparation ■ Sterile Preparation

Processing Error / Testing Considerations: To account for processing error, pH testing, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional **20 to 25%** of the required quantities of ingredients.

Special Instruction: This formula may contain one or more Active Pharmaceutical Ingredients (APIs) that may be classified as hazardous, please refer & verify the current NIOSH list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. At this time, **General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings** is informational and not compendially applicable unless otherwise specified by regulators and enforcement bodies. For information on the scope, intended applicability, and implementation context for USP General Chapter <800>, see: https://www.usp.org/compounding/general-chapter-hazardous-drugs-handling-healthcare.

This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 797* and *USP 800*, when handling hazardous drugs. Only trained and qualified personnel must prepare this formula.

All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.

Compounder needs to verify as per USP, if every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.

All required personal protective equipment (sterile and hazardous if applicable), such as but not limited to, gowns, aprons, sleeves, gloves both inner and outer if applicable, shoe covers, hairnet, head cap, beard cover, eyewear, appropriate face mask, respirator and face shield, etc., where applicable must be worn at all times. In addition, proper personnel cleansing must be done before entering the buffer or clean area.

If applicable, follow all required procedures for hazardous drug handling including but not limited to procurement, transport, storage, preparation, dispensing, administration, clean up (spills) & disposal.

Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

If you are a registered 503B facility, please refer to all relevant guidance documents including but not limited to the Code of Federal Regulations (CFR), Guidance for Industry (GFIs) and Compliance Policy Guides (CPGs).

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Dobutamine 12.5 mg/mL Intravenous Injection (Solution, 20 mL)	FIN	F 008 740

SUGGESTED PREPARATION (for 20 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): ____	Processing Error	Qty. to measure
Dobutamine Hydrochloride, USP §	0.280	g			
Sodium Metabisulfite 1% Stock Solution † §	0.4	mL			
Sodium Chloride, USP §	0.127	g			
Sterile Water for Injection, USP §	18.0	mL			
Sterile Water for Injection, USP §	q.s. to 20.0	mL			
Hydrochloric Acid 10% Solution §	As required				
Sodium Hydroxide 10% Solution §	As required				
† **Sodium Metabisulfite 1% Stock Solution**					
Sodium Metabisulfite, NF §	0.100	g	---	---	
Sterile Water for Injection, USP §	9.0	mL	---	---	
Sterile Water for Injection, USP §	q.s. to 10.0	mL	---	---	

* Takes into account increased batch size conversions and density conversions, if required.
§ Weigh / measure just prior to use.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Dobutamine 12.5 mg/mL Intravenous Injection (Solution, 20 mL)	FIN	F 008 740

Preparatory Instruction

IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique

1. **Equipment sterilization:**

   Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.

2. † **Sodium Metabisulfite 1% Stock Solution preparation:**

   A. Incrementally add the Sodium Metabisulfite (0.100 g) to the Sterile Water for Injection (9.0 mL).

      Specifications: Continuously mix until all solid particles have completely dissolved.

      End result: Homogeneous liquid-like solution.

   B. Add additional Sterile Water for Injection to the mixture (Step 4A) to fill to the required batch size (10.0 mL).

      Specifications: Continuously mix.

      End result: Homogeneous liquid-like solution.

3. **Powder-liquid preparation:**

   A. In the given order, sequentially add the following ingredients to the Sterile Water for Injection (18.0 mL *plus* processing error adjustments):

      -Sodium Metabisulfite 1% Stock Solution (0.4 mL *plus* processing error adjustments)
      -Dobutamide Hydrochloride
      -Sodium Chloride

      Specifications: Continuously mix.

      End result: Homogeneous liquid-like solution.

      Note: Add the next ingredient, once the previous one has been completely added and dissolved.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Dobutamine 12.5 mg/mL Intravenous Injection (Solution, 20 mL)	FIN	F 008 740

4. **pH testing:**

A. Draw an appropriate amount of the mixture (Step 3A).

B. Test the pH of the sample. It should lie between 2.5 and 5.5.

C. If the pH < 2.5, carefully add, in a dropwise fashion, the Sodium Hydroxide 10% Solution to the mixture:

1. Draw and transfer 1 or 2 drops of the Sodium Hydroxide 10% Solution to the mixture.
2. Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 10% Solution.
3. Re-test the pH.
4. Continue to add the Sodium Hydroxide 10% Solution until the pH of 2.5 to 5.5 is obtained.

IMPORTANT: Do not allow the pH to rise above 5.5.

D. If the pH > 5.5, carefully add, in a dropwise fashion, the Hydrochloric Acid 10% Solution to the mixture:

1. Draw and transfer 1 or 2 drops of the Hydrochloric Acid 10% Solution to the mixture.
2. Stir for at least 5 minutes to evenly disperse the Hydrochloric Acid 10% Solution.
3. Re-test the pH.
4. Continue to add the Hydrochloric Acid 10% Solution until the pH of 2.5 to 5.5 is obtained.

IMPORTANT: Do not allow the pH to fall below 2.5

5. **Filling to volume:**

A. Add additional Sterile Water for Injection to the above mixture to fill to the required batch size (20.0 mL *plus* processing error adjustments).

Specifications: Continuously mix, using high-shear mixing techniques.

End result: Homogeneous liquid-like dispersion.

6. **Filtering and transferring:**

Aseptically filter the solution through a 0.22-µm sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.

7. **Terminal Sterilization:**

In relation to the chemical composition of the formulation, final packaging, etc., select and validate an end-stage sterilization method and follow the manufacturer's specification.

8. **Sterility and Endotoxin testing:**

Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Dobutamine 12.5 mg/mL Intravenous Injection (Solution, 20 mL)	FIN	F 008 740

SUGGESTED PRESENTATION

Estimated Beyond-Use Date	24 hours controlled room temperature, 3 days refrigerated, or 45 days frozen, as per USP 797. BUD based on successful endotoxin test result.		Packaging Requirements	Sterile, tightly closed, light-resistant unit-dose injection vials.	
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	6	Discard container after use.	
	2	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.	7	Discard in the presence of particulate matter.	
	3	Do not use if product changes color.	8	**Preservative free solution, single use only. Discard any unused portion.**	
	4	Keep at controlled room temperature, (20°C – 25°C), refrigerated (2°C – 8°C) or frozen (-25°C to -10°C).	9	Protect from light.	
	5	Keep out of reach of children.	10	Equilibrate to room temperature before use.	
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary. **IMPORTANT: Using proper aseptic techniques, one must dilute the Dobutamine to the appropriate concentrations with the appropriate sterile diluent prior to intravenous injection. Also it must be administered accordingly as determined by the prescribing physician.**				
Patient Instructions	Contact your pharmacist in the event of adverse reactions.				

Suggested Formula	Dobutamine 12.5 mg/mL Intravenous Injection (Solution, 20 mL)	FIN	F 008 740

REFERENCES

1. Paenteral Preparations. In: Allen, LV, Jr. *The Art, Science, and Technology of Pharmaceutical Compounding Fifth Edition.* American Pharmacists Association; 2016: 399.
2. Dobutamine. In: Canadian Pharmacists Association. *Compendium of Pharmacists and Specialties, 2017*: 804.
3. Sodium Chloride. In: Sheskey, P.J., ed. *Handbook of Pharmaceutical Excipients, 8th Edition*. Pharmaceutical Press and American Pharmacists Association; 2017: 854.
4. Sodium Metabisulfite. In: Sheskey, P.J., ed. *Handbook of Pharmaceutical Excipients, 8th Edition*. Pharmaceutical Press and American Pharmacists Association; 2017: 873.
5. Dobutamine Hydrochloride. In: Brayfield, A., ed. *Martindale: The Complete Drug Reference, 38th Edition.* London, England: The Pharmaceutical Press; 2014: 165.
6. Dobutamine (Monograph). In: O'Neil MJ. *The Merck Index 15th Edition*. Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #3440.
7. Chapter 8: Buffered and Isotonic Solutions. In: Sinko, D. J. and Singh, Y. *Martin's Physical Pharmacy and Pharmaceutical Sciences, Sixth Edition.* Philadelphia, PA: Lipponcott Williams & Wilkins; 2011: 163-181.
8. Chapter 18: Tonicity, Osmoticity, Osmolality and Osmolarity. In: D.B Troy. *Remington: The Science and Practice of Pharmacy, 21st Edition.* Baltimore, MD: Lippincott Williams & Wilkins; 2006: 250~265.
9. Dobutamine Hydrochloride (Monograph). *United States Pharmacopeia XLIII / National Formulary 38.* Rockville, MD. US Pharmacopeial Convention, Inc. 2020: 1466.
10. USP <797>. *United States Pharmacopeia XLIII / National Formulary 38.* Rockville, MD. US Pharmacopeial Convention, Inc. 2020: 7037.

DISCLAIMER: THIS DOCUMENT IS COPYRIGHT© 2020 MEDISCA PHARMACEUTIQUE INC. MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.